Skip to Content

'
Lance C. Pagliaro, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler Street
Unit 1374
Houston, TX 77030
Room Number: CPB7.3458
Phone: 713-792-2830
Fax: 713-794-1446

Education & Training

Degree-Granting Education

1987 Albany Medical College, Albany, NY, MD, Medicine
1983 Amherst College, Amherst, MA, BA, Magna Cum Laude, Biology and Anthropology

Postgraduate Training

7/1992-6/1993 Clinical Fellowship, Hematology and Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1990-6/1992 Clinical Fellowship, Hematology and Medical Oncology, The George Washington University Medical Center, Washington, DC
7/1988-6/1990 Clinical Residency, Internal Medicine, The George Washington University Medical Center, Washington, DC
7/1987-6/1988 Clinical Internship, Internal Medicine, The George Washington University Medical Center, Washington, DC

Board Certifications

11/2013 American Board of Medical Oncology, Certification: 1999, Recertification: 2013
1988 National Board of Medical Examiners

Experience/Service

Academic Appointments

Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2004-8/2012
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 1995-2004
Faculty Associate, Department of Clinical Investigation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1993-1995
Junior Faculty Associate, Department of Medical Specialties, Division of Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 1992-1993

Selected Publications

Peer-Reviewed Original Research Articles

1. Fizazi K, Pagliaro L, Laplanche A, Flechon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhair JP, Linassier C, habibian MH, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol 15(13):1442-1450, 12/2014. PMID: 25456363.
2. Subbiah V, Meric-Bernstam F, Mills GB, Shaw KR, Bailey A, Rao P, Ward JF, Pagliaro LC. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent) a VEGFR1/PDGFR/c-kit/FLT3/RET/CSF1R inhibitor in a phase II trial. J Hematol Oncol 7(1). e-Pub 8/2014. PMID: 25085632.
3. Brown A, Ma Y, Danenberg K, Schuckman AK, Pinski JK, Pagliaro LC, Quinn DI, Dorff TB. Epidermal Growth Factor receptor-targeted Therapy in squamous Cell Carcinoma of the Penis: A Report of 3 Cases. Urology 83(1):159-66, 1/2014. e-Pub 11/12/2013. PMID: 24238569.
4. Flaherty A, Kim T, Giuliano A, Magliocco A, Hakky TS, Pagliaro LC, Spiess PE. Implications for human papillomavirus in penile cancer. Urol Oncol 32(1):53.e1-8, 1/2014. e-Pub 11/13/2013. PMID: 24239463.
5. Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, Feldman DR, Pagliaro LC, Miller RC, Vaughn DJ, Einhorn LH, Cox NJ, Dolan ME, for the Platinum Study Group. Chemotherapy-Induced Peripheral Neurotoxicity and Ototoxicity: New Paradigms for Translational Genomics. J Natl Cancer Inst 106(5):dju044, 2014. e-Pub 3/2014. PMID: 24623533.
6. Carthon BC, Ng CS, Pettaway CA, Pagliaro LC. Epidermal Growth Factor Receptor-Targeted Therapy in Locally Advanced or Metastatic Squamous Cell Carcinoma of the Penis. BJU Int 113:871-877, 2014. e-Pub 9/2013. PMID: 24053151.
7. Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, Waguespack SG, Naing A, Sircar K, Wood CG, Pagliaro LC, Jimenez C, Vassilopoulou-Sellin R, Habra M. Adrenocortical carcinoma: Clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol 169(6):891-9, 10/2013. e-Pub 10/2013. PMID: 24086089.
8. Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro LC. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urol Oncol 31(7):1171-7, 10/2013. e-Pub 4/2012. PMID: 22534087.
9. Sonpavde G, Pagliaro LC, Buonerba C, Dorff TB, Lee RJ, Di Lorenzo G. Penile cancer: current therapy and future directions. Ann Oncol 24(5):1179-89, 5/2013. e-Pub 1/4/2013. PMID: 23293117.
10. Rodney AJ, Tannir NM, Siefker-Radtke AO, Liu P, Walsh GL, Millikan RE, Swisher SG, Tu SM, Pagliaro LC. Survival outcomes for men with mediastinal germ-cell tumors: The University of Texas MD Anderson Cancer Center experience. Urol Oncol 30(6):879-85, Nov-Dec, 11/2012. e-Pub 10/2010. NIHMSID: NIHMS530876.
11. Osai WE, Demicco EG, Pagliaro LC. Malignant Small Round Blue Cell Tumor of the Kidney Without EWSR1 Rearrangement: Report of a Case and Review of the Literature. Clin Genitourin Cancer 10(1):63-5, 3/2012. PMID: 22153153.
12. Mathew P, Tannir N, Tu SM, Wen S, Guo CC, Marcott V, Bekele BN, Pagliaro L. Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemother Pharmacol 68(4):889-96, 10/2011. PMID: 21290244.
13. Hegarty PK, Suh J, Fisher MB, Taylor J, Nguyen TH, Ivan D, Prieto VG, Pagliaro LC, Pettaway CA. Penoscrotal Extramammary Paget Disease: The University of Texas M. D. Anderson Cancer Center (MDACC) Contemporary Experience. J Urol 186(1):97-102, 7/2011. e-Pub 5/14/2011. PMID: 21571343.
14. Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC. Persistent, biologically meaningful prostate cancer after one year of androgen ablation and docetaxel treatment. J Clin Oncol 29(18):2574-81, 6/20/2011. e-Pub 5/23/2011. PMCID: PMC3138635.
15. Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the department of defense prostate cancer clinical trials consortium. Cancer 117(11):2419-25, 6/2011. e-Pub 12/2010. PMID: 24048789.
16. Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant Paclitaxel, Ifosfamide, and Cisplatin Chemotherapy for Metastatic Penile Cancer: A Phase II Study. J Clin Oncol 28(24):3851-7, 8/20/2010. e-Pub 7/12/2010. PMCID: PMC2940402.

Invited Articles

1. Spiess PE, Horenblas S, Pagliaro LC, Biagioli MC, Crook J, Clark PE, Greenberg RE, Ercole CE. Current concepts in penile cancer. J Natl Compr Canc Netw 11(5):617-24, 5/2013. PMID: 23667210.
2. Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 11(5):594-615, 5/2013. PMID: 23667209.
3. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Bladder cancer. J Natl Compr Canc Netw 11(4):446-75, 4/2013. PMID: 23584347.
4. Pagliaro LC, Tannir N, Sircar K, Jonasch E. Systemic therapy for sarcomatoid renal cell carcinoma. Expert Rev Anticancer Ther 11(6):913-20, 6/2011. PMID: 21707288.
5. Jonasch E, Pagliaro LC, Tannir NM. Long-term management of patients with metastatic renal cell carcinoma on targeted agents. Expert Rev Anticancer Ther 10(12):1883-9, 12/2010. PMID: 21110755.
6. Pettaway CA, Pagliaro L, Theodore C, Haas G. Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer. Urology 76(2 Suppl 1):S58-65, 8/2010. PMID: 20691886.
7. Pagliaro LC. Testicular Cancer: When Less is More. Curr Oncol Rep 12(4):271-77, 7/2010. PMID: 20443156.

Last updated: 12/3/2014